Abstract
In 2012 CNS & Neurological Disorders - Drug Targets will enter its 11th year of publication. This year will also mark my third year as Editor-in-Chief.
Since taking the helm of the journal a number of changes have been introduced, one of my first having been to renew and expand our Editorial Advisory Board to include a broader base of expertise in this incredibly fast-moving area of science.
Starting last year, and continuing in 2012 CNS & Neurological Disorders - Drug Targets expands its production calendar to 8 issues per year, up from the previous frequency of 6 issues. Other developments, which I believe will strengthen interest in the journal and encourage an increasingly diverse range of topic submissions is the inclusion, apart from reviews, of both full-length and letter-type research articles as well as clinical case reports. We have added also sections dealing with short Research Highlights discussing recent, high impact publications of relevance to the journal's mission together with reports on meetings.
A number of cutting-edge Hot Topic issues are in the works for 2012, including nanoneuroscience, endocannabinoids, novel strategies for neuropsychiatric disorders, and purinergic receptor signaling. CNS & Neurological Disorders - Drug Targets is always open to theme issue proposals from our readers, and I encourage you to submit your ideas for consideration.
With best wishes for a productive New Year,
CNS & Neurological Disorders - Drug Targets
Title:Message from the Editor-in-Chief
Volume: 11 Issue: 1
Author(s): Stephen D. Skaper
Affiliation:
Abstract:
In 2012 CNS & Neurological Disorders - Drug Targets will enter its 11th year of publication. This year will also mark my third year as Editor-in-Chief.
Since taking the helm of the journal a number of changes have been introduced, one of my first having been to renew and expand our Editorial Advisory Board to include a broader base of expertise in this incredibly fast-moving area of science.
Starting last year, and continuing in 2012 CNS & Neurological Disorders - Drug Targets expands its production calendar to 8 issues per year, up from the previous frequency of 6 issues. Other developments, which I believe will strengthen interest in the journal and encourage an increasingly diverse range of topic submissions is the inclusion, apart from reviews, of both full-length and letter-type research articles as well as clinical case reports. We have added also sections dealing with short Research Highlights discussing recent, high impact publications of relevance to the journal's mission together with reports on meetings.
A number of cutting-edge Hot Topic issues are in the works for 2012, including nanoneuroscience, endocannabinoids, novel strategies for neuropsychiatric disorders, and purinergic receptor signaling. CNS & Neurological Disorders - Drug Targets is always open to theme issue proposals from our readers, and I encourage you to submit your ideas for consideration.
With best wishes for a productive New Year,
Export Options
About this article
Cite this article as:
Stephen D. Skaper , Message from the Editor-in-Chief, CNS & Neurological Disorders - Drug Targets 2012; 11 (1) . https://dx.doi.org/10.2174/187152712799960763
DOI https://dx.doi.org/10.2174/187152712799960763 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trends in Photocatalysis Research from the Year 2000 to 2020
Current Organocatalysis The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design
Current Alzheimer Research Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement
Current Topics in Medicinal Chemistry Role of Retinoids, Rexinoids and Thyroid Hormone in the Expression of Cytochrome P450 Enzymes
Current Drug Metabolism Drug Treatment of Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-picking) Disorder, and Nail-biting (Onychophagia)
Current Neuropharmacology Recent Advances in Fluorescent Probes for Monitoring of Hydrogen Sulfide
Current Medicinal Chemistry Antidepressants Alter Mesostriatal Dopamine Interactions with Serotonin Signaling
Current Psychiatry Reviews Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism The Role of Coagulation and Fibrinolysis in the Pathogenesis of Acute Lung Injury
Current Respiratory Medicine Reviews Anti-Inflammatory Effects of Physical Activity in Relationship to Improved Cognitive Status in Humans and Mouse Models of Alzheimers Disease
Current Alzheimer Research Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research Hydroxytyrosol, a Phenyl Ethyl Alcohol with Health Effects
Current Organic Chemistry Increased Prevalence of Vestibular Loss in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Current Pharmaceutical Design Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Current Neuropharmacology A New Approach to Synthesis of Benzyl Cinnamate: Kinetic and Thermodynamic Investigation
Current Catalysis Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Evaluation of the Antipsychotic Effects of 2-(dimethylamino)- and 2-(methylamino)-7H-naphtho[1,2,3-de]quinolin-7-one Derivatives in Experimental Model of Psychosis in Mice
Current Topics in Medicinal Chemistry